PDCD1 and neoplasm: Engineering CAR T cells or TCR-transgenic T cells that are refractory to inhibition by immune checkpoints represents a promising future avenue to specifically protect engineered tumor-specific T cells against functional impairment through inhibitory pathways such as PD-1/PD-L1.